Stockreport

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Paris, March 18, 2026 The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylcerami [Read more]